PLCG1 and RAC1 orchestrate adaptive cellular programs driving osimertinib-tolerant persister cell formation in malignant pleural effusion-associated non-small cell lung cancer.
- DOI
- 10.1016/j.ejps.2026.107608
- Published
- 2026 Oct 1
- Container
- European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejps.2026.107608,
title = {PLCG1 and RAC1 orchestrate adaptive cellular programs driving osimertinib-tolerant persister cell formation in malignant pleural effusion-associated non-small cell lung cancer.},
author = {Tiong TY and Wang CY and Chen Y and Lin YH and Changchien CY and Chian CF and Tsai CL},
year = {2026},
journal = {European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences},
doi = {10.1016/j.ejps.2026.107608},
url = {https://doi.org/10.1016/j.ejps.2026.107608}
}RIS
TY - JOUR TI - PLCG1 and RAC1 orchestrate adaptive cellular programs driving osimertinib-tolerant persister cell formation in malignant pleural effusion-associated non-small cell lung cancer. AU - Tiong TY AU - Wang CY AU - Chen Y AU - Lin YH AU - Changchien CY AU - Chian CF AU - Tsai CL PY - 2026 JO - European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences DO - 10.1016/j.ejps.2026.107608 UR - https://doi.org/10.1016/j.ejps.2026.107608 ER -
APA
TY, T., CY, W., Y, C., YH, L., CY, C., CF, C., & CL, T. (2026). PLCG1 and RAC1 orchestrate adaptive cellular programs driving osimertinib-tolerant persister cell formation in malignant pleural effusion-associated non-small cell lung cancer.. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2026.107608
Source records
- pubmed · retrieved 2026-09-26T22:59:03.725Z